Earli combines wet lab experiments with AI in a continuous feedback loop. They test massive libraries of synthetic DNA promoter sequences, feed the performance results into a Large Language Model (LLM), which then designs new, potentially more effective sequences. This iterative process rapidly optimizes their cancer-specific genetic switches.

The current, tangible role of AI in medicine is its ability to detect subtle patterns in large datasets, radically accelerating drug discovery. Breakthroughs like AlphaFold, which predicts protein shapes, are the true near-term game-changers for aging research, while molecular manufacturing remains distant.

The "AI vs. Dog Cancer" story shows that current AI's power is not autonomous discovery, but its ability to act as a research assistant, enabling motivated non-experts to orchestrate complex scientific projects by finding and coordinating with human experts.

The future of AI in drug discovery is shifting from merely speeding up existing processes to inventing novel therapeutics from scratch. The paradigm will move toward AI-designed drugs validated with minimal wet lab reliance, changing the key question from "How fast can AI help?" to "What can AI create?"

AlphaFold's success in identifying a key protein for human fertilization (out of 2,000 possibilities) showcases AI's power. It acts as a hypothesis generator, dramatically reducing the search space for expensive and time-consuming real-world experiments.

Novonesis has shifted enzyme discovery from the lab to computers. Using AI tools like AlphaFold, they predict protein structures and identify new enzyme families based on structural motifs rather than sequence similarity. This allows them to find novel functionalities much faster than traditional methods.

An ordinary citizen, Paul Cunningham, used off-the-shelf AI like ChatGPT and Google's AlphaFold to design a custom mRNA vaccine that shrank his dog's tumor by 75%. This demonstrates the revolutionary potential of AI to empower individuals to solve complex scientific problems once exclusive to specialized experts.

Following the success of AlphaFold in predicting protein structures, Demis Hassabis says DeepMind's next grand challenge is creating a full AI simulation of a working cell. This 'virtual cell' would allow researchers to test hypotheses about drugs and diseases millions of times faster than in a physical lab.

The current model of medical regulation, exemplified by the FDA, is poised to break. When AI can generate personalized cures, individuals in desperate situations will bypass official channels. This will create real-world evidence outside of clinical trials, forcing regulatory bodies to react rather than control, and leading to chaotic deregulation.